search icon

    Market Snapshot

    • S&P Futures

      3,809.5

    • Dow Futures

      30,868

    • Nasdaq Futures

      11,633.25

    blog search icon

    BridgeBio Pharma, Inc.

    (NASDAQ:BBIO)

    $9.08

    $0.24

    2.71%

    BridgeBio Pharma, Inc. Chart

    BBIO Stock Price Today

    BridgeBio Pharma, Inc. (BBIO) stock rallied over 2.71% intraday to trade at $9.08 a share on NASDAQ. The stock opened with a gain of 4.37% at $8.79 and touched an intraday high of $9.25, rising 2.71% against the last close of $8.84. The stock went to a low of $8.54 during the session.

    Stock Snapshot

    $8.84

    Prev. Close

    1.32 Billion

    Market Cap

    $8.54

    Day Low

    $8.79

    Open

    145.88 Million

    Number of Shares

    $9.25

    Day High

    -

    P/E ratio

    -4.08

    EPS (TTM)

    5.67

    Cash Flow per Share

    19.45

    Free Float in %

    -5.05

    Book Value

    1,684,342

    Volume

    BridgeBio Pharma, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-30$8.79$9.25$8.54$9.081,684,342
    2022-06-29$8.7$8.98$8.33$8.841,277,700
    2022-06-28$9.26$9.54$8.69$8.71,818,800
    2022-06-27$9.22$9.425$8.58$9.341,473,500
    2022-06-24$9.07$9.43$8.69$9.242,815,600
    2022-06-23$8.49$9.08$8.33$9.082,265,300
    2022-06-22$7.78$8.789$7.77$8.452,329,900
    2022-06-21$7.82$8.419$7.795$7.972,990,900
    2022-06-17$6.62$7.9$6.552$7.654,084,100
    2022-06-16$6.42$6.675$6.083$6.512,215,300

    Contact Details

    421 Kipling Street
    Palo Alto, CA 94301
    United States

    Webiste:BBIO

    650 391 9740

    Company Information

    Employees-

    Beta-

    Sales or Revenue69.72 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

    Frequently Asked Questions

    icon

    What is the current BridgeBio Pharma, Inc. (BBIO) stock price?

    BridgeBio Pharma, Inc. (NASDAQ: BBIO) stock price is $9.08 as of the last check on Thursday, June 30. During the trading session, BBIO stock reached the peak price of $9.25 while $8.54 was the lowest point it dropped to.

    icon

    BBIO's industry and sector of operation?

    The NASDAQ listed BBIO is part of Biotechnology industry that operates in the broader Health Care sector. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.

    icon

    Who are the executives of BBIO?

    Dr. Neil Kumar Ph.D.
    Co-Founder, CEO & Director
    Dr. Charles J. Homcy M.D.
    Chairman of Pharmaceuticals & Lead Director
    Ms. Yi Ching Yau
    Chief Accounting Officer
    Dr. Frank McCormick Ph.D.
    Chairman of Oncology

    icon

    What is the BBIO stock price today?

    BBIO stock traded closed the last session at $9.08, which is $0.24 or 2.71% lower than its previous close of $8.84. BBIO's current trading price is 82.33% lower than its 52-week high of $65.33 where as its distance from 52-week low of 4.98% is -86.10%.

    icon

    How many employees does BBIO have?

    Number of BBIO employees currently stands at -. BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, United States.

    icon

    Link for BBIO official website?

    Official Webiste of $BBIO is: https://www.bridgebio.com

    icon

    How do I contact BBIO?

    BBIO could be contacted at BBIO operates from 421 Kipling Street, Palo Alto, CA 94301, United States, or at phone #650 391 9740 and can also be accessed through its website.

    icon

    How many shares of BBIO are traded daily?

    BBIO stock volume for the day was 1,684,342 shares while in the previous session number of BBIO shares traded was 1,684,342 . The average number of BBIO shares traded daily for last 3 months was 2.15 Million.

    icon

    How much did BBIO change today?

    The percentage change in BBIO stock occurred in the recent session was 2.71% while the dollar amount for the price change in BBIO stock was $0.24.

    icon

    What price range BBIO stock been trading in?

    In the recent session, the day high for BBIO stock was $9.25 while the low for BBIO stock touched on the day was $8.54.

    icon

    What is the market cap of BBIO currently?

    The market value of BBIO currently stands at 1.32 Billion with its latest stock price at $9.08 and 145.88 Million of its shares outstanding.